Terumo (OTCMKTS:TRUMY) Shares Gap Down - Should You Sell?

Key Points

• Terumo Corp. shares opened at $16.18 after gapping down from a previous close of $16.61, with last traded price at $16.86.
• The company reported $0.20 earnings per share for the last quarter, exceeding estimates and showcasing a net margin of 12.09%.
• Terumo has a market capitalization of $24.95 billion and operates in multiple segments, including Cardiac and Vascular, Medical Care Solutions, and Blood and Cell Technologies.

Shares of Terumo Corp. (OTCMKTS:TRUMY - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $16.61, but opened at $16.18. Terumo shares last traded at $16.86, with a volume of 1,262 shares traded.

Terumo Stock Performance

The stock has a fifty day moving average price of $17.39 and a two-hundred day moving average price of $17.90. The company has a market cap of $24.95 billion, a P/E ratio of 29.57 and a beta of 0.79. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.64 and a quick ratio of 1.53.

Terumo (OTCMKTS:TRUMY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.03. Terumo had a net margin of 12.09% and a return on equity of 9.19%. The firm had revenue of $1.76 billion for the quarter, compared to analyst estimates of $1.80 billion.

Terumo Company Profile

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.